OBJECTIVE: vMIP-II (viral macrophage inflammatory protein 2)/vCCL2 (viral chemotactic cytokine ligand 2) binds to multiple chemokine receptors, and vMIP-II-based positron emission tomography tracer (64Cu-DOTA-vMIP-II: vMIP-II tracer) accumulates at atherosclerotic lesions in mice. Given that it would be expected to react with multiple chemokine receptors on monocytes and macrophages, we wondered if its accumulation in atherosclerosis lesion-bearing mice might correlate with overall macrophage burden or, alternatively, the pace of monocyte recruitment. Approach and Results: We employed a mouse model of atherosclerosis regression involving adenoassociated virus 8 vector encoding murine Apoe (AAV-mApoE) treatment of Apoe-/- mice where the pace of monocyte recruitment slows before macrophage burden subsequently declines. Accumulation of 64Cu-DOTA-vMIP-II at Apoe-/- plaque sites was strong but declined with AAV-mApoE-induced decline in monocyte recruitment, before macrophage burden reduced. Monocyte depletion indicated that monocytes and macrophages themselves were not the only target of the 64Cu-DOTA-vMIP-II tracer. Using fluorescence-tagged vMIP-II tracer, competitive receptor blocking with CXCR4 antagonists, endothelial-specific Cre-mediated deletion of CXCR4, CXCR4-specific tracer 64Cu-DOTA-FC131, and CXCR4 staining during disease progression and regression, we show endothelial cell expression of CXCR4 is a key target of 64Cu-DOTA-vMIP-II imaging. Expression of CXCR4 was low in nonplaque areas but strongly detected on endothelium of progressing plaques, especially on proliferating endothelium, where vascular permeability was increased and monocyte recruitment was the strongest. CONCLUSIONS: Endothelial injury status of plaques is marked by CXCR4 expression and this injury correlates with the tendency of such plaques to recruit monocytes. Furthermore, our findings suggest positron emission tomography tracers that mark CXCR4 can be used translationally to monitor the state of plaque injury and monocyte recruitment.
OBJECTIVE: vMIP-II (viral macrophage inflammatory protein 2)/vCCL2 (viral chemotactic cytokine ligand 2) binds to multiple chemokine receptors, and vMIP-II-based positron emission tomography tracer (64Cu-DOTA-vMIP-II: vMIP-II tracer) accumulates at atherosclerotic lesions in mice. Given that it would be expected to react with multiple chemokine receptors on monocytes and macrophages, we wondered if its accumulation in atherosclerosis lesion-bearing mice might correlate with overall macrophage burden or, alternatively, the pace of monocyte recruitment. Approach and Results: We employed a mouse model of atherosclerosis regression involving adenoassociated virus 8 vector encoding murine Apoe (AAV-mApoE) treatment of Apoe-/- mice where the pace of monocyte recruitment slows before macrophage burden subsequently declines. Accumulation of 64Cu-DOTA-vMIP-II at Apoe-/- plaque sites was strong but declined with AAV-mApoE-induced decline in monocyte recruitment, before macrophage burden reduced. Monocyte depletion indicated that monocytes and macrophages themselves were not the only target of the 64Cu-DOTA-vMIP-II tracer. Using fluorescence-tagged vMIP-II tracer, competitive receptor blocking with CXCR4 antagonists, endothelial-specific Cre-mediated deletion of CXCR4, CXCR4-specific tracer 64Cu-DOTA-FC131, and CXCR4 staining during disease progression and regression, we show endothelial cell expression of CXCR4 is a key target of 64Cu-DOTA-vMIP-II imaging. Expression of CXCR4 was low in nonplaque areas but strongly detected on endothelium of progressing plaques, especially on proliferating endothelium, where vascular permeability was increased and monocyte recruitment was the strongest. CONCLUSIONS: Endothelial injury status of plaques is marked by CXCR4 expression and this injury correlates with the tendency of such plaques to recruit monocytes. Furthermore, our findings suggest positron emission tomography tracers that mark CXCR4 can be used translationally to monitor the state of plaque injury and monocyte recruitment.
Authors: Vidya V Kunjathoor; Diane S Chiu; Kevin D O'Brien; Renée C LeBoeuf Journal: Arterioscler Thromb Vasc Biol Date: 2002-03-01 Impact factor: 8.311
Authors: G S Kuschert; F Coulin; C A Power; A E Proudfoot; R E Hubbard; A J Hoogewerf; T N Wells Journal: Biochemistry Date: 1999-09-28 Impact factor: 3.162
Authors: J A Ambrose; M A Tannenbaum; D Alexopoulos; C E Hjemdahl-Monsen; J Leavy; M Weiss; S Borrico; R Gorlin; V Fuster Journal: J Am Coll Cardiol Date: 1988-07 Impact factor: 24.094
Authors: Nicholas R Evans; Jason M Tarkin; Mohammed M Chowdhury; Elizabeth A Warburton; James H F Rudd Journal: Curr Atheroscler Rep Date: 2016-06 Impact factor: 5.113
Authors: Nicholas Kipshidze; George Dangas; Mykola Tsapenko; Jeffrey Moses; Martin B Leon; Michael Kutryk; Patrick Serruys Journal: J Am Coll Cardiol Date: 2004-08-18 Impact factor: 24.094
Authors: W C Little; M Constantinescu; R J Applegate; M A Kutcher; M T Burrows; F R Kahl; W P Santamore Journal: Circulation Date: 1988-11 Impact factor: 29.690
Authors: Jason M Tarkin; Marc R Dweck; Nicholas R Evans; Richard A P Takx; Adam J Brown; Ahmed Tawakol; Zahi A Fayad; James H F Rudd Journal: Circ Res Date: 2016-02-19 Impact factor: 17.367
Authors: Tzu-Tang Wei; Mark Chandy; Masataka Nishiga; Angela Zhang; Kaavya Krishna Kumar; Dilip Thomas; Amit Manhas; Siyeon Rhee; Johanne Marie Justesen; Ian Y Chen; Hung-Ta Wo; Saereh Khanamiri; Johnson Y Yang; Frederick J Seidl; Noah Z Burns; Chun Liu; Nazish Sayed; Jiun-Jie Shie; Chih-Fan Yeh; Kai-Chien Yang; Edward Lau; Kara L Lynch; Manuel Rivas; Brian K Kobilka; Joseph C Wu Journal: Cell Date: 2022-04-29 Impact factor: 66.850
Authors: Xia Lu; Raffaella Calabretta; Wolfgang Wadsak; Alexander R Haug; Marius Mayerhöfer; Markus Raderer; Xiaoli Zhang; Jingle Li; Marcus Hacker; Xiang Li Journal: Life (Basel) Date: 2022-07-12